Olanzapine: Interaction study with imipramine

Journal of Clinical Pharmacology

Volumn 37, Issue 10, 1997, Pages 971-978

  Callaghan, John T ^a,b   Cerimele, Benito J ^a   Kassahun, Kelem J ^a   Nyhart Jr , Eldon H ^a   Hoyes Beehler, Pamela J ^a,c   Kondraske, George V ^a,c  

^a WISHARD MEMORIAL HOSPITAL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; IMIPRAMINE; OLANZAPINE; SEROTONIN RECEPTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; MALE; NORMAL HUMAN; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 0030734670     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04272.x     Document Type: Article

References (18)

1. Ring BJ, Binkley SN, VandenBranden M, Wrighton SA: In Vitro Interaction of Olanzapine with Human Cytochromes P450 CYP2C9, CYP2C19, CYP2D6, and CYP3A. Br J Clin Pharmacol 1996;41:181-186.
2. Bergstom RF, Callaghan JT, Cerimele BJ, Kassahun K, Nyhart Jr EH, Patel BR: Biopharmaceutics Integrated Summary Volume. Reference on file with Eli Lilly and Company, 1995.
3. Lemoine A, Gautier JM., Azoulay D et al: Major Pathway of Imipramine Metabolism is Catalyzed by Cytochromes P-450 1A2 and P-450 3A4 in Human Liver. Mol Pharmacol 1993;43:827-832.
4. Skjelbo E, Brosen K: Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-261.
5. Brosen K, Otton SV, Gram LF: Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1986;40(5):543-549.
6. Spina E, Birgersson C, von Bahr C, Ericsson O, Mellstrom B, Steiner E, Sjoqvist F: Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 1984;36(5): 677-1.
7. Skjelbo E, Brosen K: Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1993;35:331-334.
8. Chiba K, Saitoh A, Koyama E, Tani M, Hayashi M, Ishizaki T: The role of S-mephenytoin 4′-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 1994; 37:237-2.
9. Madsen H, Nielsen KK, Brosen K: Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms-a population study. Br J Clin Pharmacol 1995;39:433-439.
10. Dugovic C, Wauquier A, Janssen PA: Differential effects of the new antipsychotic risperidone on sleep and wakefulness in the rat. Neuropharmacology 1989;28(12):1431-1433.
11. Ruther E, Davis L, Papousek M, Reichinger M, Reiter H, Rudolph M: [Pharmacological influence on central serotonergic mechanisms in man and its consequences on sleep (author's transl)]. Arzneimittelforschung 1976;26(6):1071-1073.
12. Touyz-SW, Beumont PJ, Saayman GS, Zahow T: A psychophysiological investigation of the short-term effects of clozapine upon sleep parameters of normal young adults. Biol Psychiatry 1977;12(6):801-822.
13. Lemberger L, Fuller RW, Zerbe RL: Use of Specific Serotonin Uptake Inhibitors as Antidepressants. Clin Neuropharmacol 1985; 8(4), 299-17.
14. Plenge P, Mellerup ET, Laursen H: Regional distribution of the serotonin transport complex in human brain, identified with 3H-paroxetine, 3H-citalopram and 3H-imipramine. Prog Neuropsychopharmacol Biol Psychiatry 1990;14(1):61-72.
15. Kondraske GV: A PC-based performance measurement laboratory system. J Clin Engr 1990;15(6):467-78.
16. Kondraske GV, Vasta PJ: Measurement of information processing performance capacities. In J Bronzino (Ed.), The Biomedical Engineering Handbook. Boca Raton: CRC Press, 1995;2209-2222.
17. Callaghan JT, Bergstrom RF, Cerimele BJ, Kassahun K, Nyhart Jr EH, Kondraske GV, Hoyes-Beehler PJ: Olanzapine/Ethanol Drug Interaction Trial. Manuscript in preparation.
18. Ring BJ, Catlow J, Lindsay TJ, et al: Identification of the Human Enzymes Responsible for the Formation of the Major In Vitro Oxidative Metabolites of Olanzapine. J Pharmacol Exp Ther 1995; 276(2):658-6.